Kura Oncology, Inc. (KURA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Kura Oncology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 11.89 at 4:00 am ET, low 11.66 at 10:00 am ET.
the bull case· 4
+9.67%
ten largest reporting managers increasing their aggregate shares over the latest quarter
13fJun 30 '26219
managers reporting a position in the latest quarterly filings
13fJun 30 '264
funds on file reporting a position in KURA among active institutional holders
n-portas of Jun 30 '263
disclosed supplier and customer ties in SEC filings linking the company to peers
sec filingsedgarthe bear case· 4
9 of 24
largest reporting managers cut their stake in the latest quarter indicating selling activity
13fJun 30 '2627
managers whose positions together make up four fifths of the reported value concentrate ownership
13fJun 30 '260.32%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '268 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 6 companies Kura Oncology, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
220 managers report a position worth $959.6M between them, and 27 of them hold 80% of it.
tall tick = annual report · 1 on record
KURA (Kura Oncology, Inc.) has 2 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.